Building better breakpoints: data and methods needed to determine breakpoints for new agents GARDP

683 views - 5 years ago

Introduction to GARDP by Dr Manica Balasegaram, Director GARDP

739 views - 7 years ago

#ResistResistance: Developing Treatments to Transform and Save Lives GARDP

1.2K views - 4 years ago

AMR R&D efforts in the CMC and formulation arena: Do it right the first time GARDP

394 views - 4 years ago

Animal models to study the activity of antibiotics GARDP

669 views - 3 years ago

Bringing new treatments for drug resistant infections to all who need them GARDP

787 views - 5 years ago

Developing antibiotics for children – medical need and regulatory challenges GARDP

235 views - 5 years ago

5BY25 - Live Webinar / Q&A with Manica Balasegaram GARDP

199 views - 6 years ago

New approaches to antibiotic discovery GARDP

826 views - 3 years ago

Converting Gram-positive-only compounds into broad-spectrum antibiotics GARDP

1.2K views - 6 years ago

Q&A: GARDP and Venatorx collaboration to develop new treatment for multidrug-resistant infections GARDP

569 views - 5 years ago

Manica Balasegaram explains why GARDP is developing a treatment for gonorrhoea GARDP

305 views - 6 years ago

How can non profit drug developers counter AMR? GARDP

185 views - 2 years ago

Non traditional antibacterial therapeutic options and challenges GARDP

571 views - 6 years ago

Challenges of developing antibiotic combinations GARDP

828 views - 3 years ago

Testing for the potential of emergence of antimicrobial resistance GARDP

699 views - 6 years ago

Clinical trial platforms for new and neglected antimicrobials GARDP

305 views - 2 years ago

Openly accessible resources for the global antimicrobial R&D community GARDP

215 views - 4 years ago

Clinical development of antimicrobials – Phase 1 development challenges GARDP

402 views - 5 years ago

Assay development for measuring antibiotic accumulation in Gram negative bacteria GARDP

922 views - 5 years ago